SAN DIEGO--(BUSINESS WIRE)--Dec. 6, 2017--
Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical
company dedicated to the development of best-in-class therapeutics that
improve and extend the lives of patients with cancer, today announced
the pricing of its initial public offering of 6,250,000 shares of common
stock at a public offering price of $24.00 per share for aggregate gross
proceeds of approximately $150 million. All of the shares of common
stock are being offered by Odonate. In addition, Odonate has granted the
underwriters a 30-day option to purchase up to 937,500 additional shares
of its common stock at the initial public offering price, less the
underwriting discount. The shares are expected to begin trading on the
NASDAQ Global Select Market on December 7, 2017 under the ticker symbol
“ODT.” The offering is expected to close on December 11, 2017, subject
to customary closing conditions.
Goldman Sachs & Co. LLC and Jefferies are acting as joint book-running
managers for the offering. Cowen is also acting as a bookrunner for the
A registration statement relating to these securities has been filed
with and was declared effective by the Securities and Exchange
Commission (SEC) on December 6, 2017. This offering is being made only
by means of a prospectus, copies of which may be obtained from Goldman
Sachs & Co. LLC (Attention Prospectus Department, 200 West Street, New
York, NY 10282; telephone: 866-471-2526); Jefferies LLC (Attention
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor,
New York, NY 10022; telephone: 877-821-7388); or Cowen and Company, LLC
(c/o Broadridge Financial Services, Attention Prospectus Department,
1155 Long Island Avenue, Edgewood, NY, 11717; telephone: 631-274-2806).
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the
development of best-in-class therapeutics that improve and extend the
lives of patients with cancer. The Company’s initial focus is on the
development of tesetaxel, a novel, orally administered chemotherapy
agent belonging to the taxane class. Odonate’s goal for tesetaxel is to
develop an effective chemotherapy choice for patients that provides
quality-of-life advantages over current alternatives.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171206006437/en/
Source: Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc.
John G. Lemkey, 858-731-8180